Figure 2.
![PFS based on sustained MRD negativity (10−5; ≥12 months) in MAIA, ALCYONE, and in both studies pooled. Kaplan-Meier estimates of PFS by sustained MRD negativity lasting ≥12 months among patients in the ITT populations. MRD status was assessed at a threshold of 1 tumor cell per 105 white blood cells. Red lines show MRD-negative patient populations and blue lines show MRD-positive patient populations (D-Rd/Rd shown for MAIA [A]; D-VMP/VMP for ALCYONE [B]; and D-Rd/Rd/D-VMP/VMP for all studies combined [C]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/139/4/10.1182_blood.2020010439/3/bloodbld2020010439f2.png?Expires=1722777101&Signature=xcv0577BYSptVu6RRzXjncmX6B5GDME1hJMKLBM17gOa8CrkAXLh2FpurPWXef~Qe1I6SUeABEkZf02GsqH4-ltK3XGBehwQj2ysDdx3tvLZrkNN1zs1rOM7sa~stptt3aIAKo4UJRfbWY6lwkuKI3gXxI-49B9UcVOsoRADJjJMz-aB8swhycX~eROgk-og-7d75ZMM1vYhDrYkm7lm~s7eAwxtVMHc8Y7Vhw8Nii9mafxtH2H4wdPWjHutKYnJap1ttKK9dUrb-R2Cgtx6CaAjs~sEkPpxOA6zoo9O2VKFU6OvovYZZL6yK6uD7BP7lIItBHKxxdETWat1iMZ83A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PFS based on sustained MRD negativity (10−5; ≥12 months) in MAIA, ALCYONE, and in both studies pooled. Kaplan-Meier estimates of PFS by sustained MRD negativity lasting ≥12 months among patients in the ITT populations. MRD status was assessed at a threshold of 1 tumor cell per 105 white blood cells. Red lines show MRD-negative patient populations and blue lines show MRD-positive patient populations (D-Rd/Rd shown for MAIA [A]; D-VMP/VMP for ALCYONE [B]; and D-Rd/Rd/D-VMP/VMP for all studies combined [C]).